BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. Journal of Hepatology 2021;75:S101-17. [DOI: 10.1016/j.jhep.2020.11.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, Burra P, Angeli P, Senzolo M, Simioni P. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100493] [Reference Citation Analysis]
2 Jalan R, Szabo G. New concepts and perspectives in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S1-2. [PMID: 34039481 DOI: 10.1016/j.jhep.2020.12.008] [Reference Citation Analysis]
3 Lin S, Zhang H, Wang X, Lin T, Chen Z, Liu J, Wang J. Abundance of Lipopolysaccharide Heptosyltransferase I in Human Gut Microbiome and Its Association With Cardiovascular Disease and Liver Cirrhosis. Front Microbiol 2021;12:756976. [PMID: 34917047 DOI: 10.3389/fmicb.2021.756976] [Reference Citation Analysis]
4 Ferrarese A, Passigato N, Cusumano C, Gemini S, Tonon A, Dajti E, Marasco G, Ravaioli F, Colecchia A. Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice. World J Hepatol 2021; 13(8): 840-852 [PMID: 34552691 DOI: 10.4254/wjh.v13.i8.840] [Reference Citation Analysis]
5 Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol 2022;76:1379-91. [PMID: 35589257 DOI: 10.1016/j.jhep.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zeng S, Schnabl B. Roles for the mycobiome in liver disease. Liver Int 2022. [PMID: 34995410 DOI: 10.1111/liv.15160] [Reference Citation Analysis]
7 Schulz MS, Gu W, Schnitzbauer AA, Trebicka J. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int 2022;35:10108. [DOI: 10.3389/ti.2022.10108] [Reference Citation Analysis]
8 Onorato L, Monari C, Capuano S, Grimaldi P, Coppola N. Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review. Antibiotics 2022;11:232. [DOI: 10.3390/antibiotics11020232] [Reference Citation Analysis]
9 Wu J, Bortolanza M, Zhai G, Shang A, Ling Z, Jiang B, Shen X, Yao Y, Yu J, Li L, Cao H. Gut microbiota dysbiosis associated with plasma levels of Interferon-γ and viral load in patients with acute hepatitis E infection. J Med Virol 2022;94:692-702. [PMID: 34549810 DOI: 10.1002/jmv.27356] [Reference Citation Analysis]
10 Kremer WM, Gairing SJ, Kaps L, Ismail E, Kalampoka V, Hilscher M, Michel M, Siegel E, Schattenberg JM, Galle PR, Sprinzl MF, Wörns MA, Nagel M, Labenz C. Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany. Ann Hepatol 2022;:100719. [PMID: 35460883 DOI: 10.1016/j.aohep.2022.100719] [Reference Citation Analysis]